References
- Gearing AJ. Targeting Toll-like receptors for drug development: a summary of commercial approaches. Immunol. Cell Biol.85(6), 490–494 (2007).
- Hemmi H, Takeuchi O, Kawai T et al. A Toll-like receptor recognizes bacterial DNA. Nature408, 740–745 (2000).
- Wagner E, Zenke M, Cotton M, Beug H, Birnstiel ML. Transferrin–polycation conjugates as carriers for DNA uptake into cells. Proc. Natl Acad. Sci. USA94, 3262–3267 (1990).
- Shen WC, Ryser HJ. Conjugation of poly-L-lysine to albumin and horseradish peroxidase: a novel method of enhancing the cellular uptake of proteins. Proc. Natl Acad. Sci. USA75, 1872–1876 (1978).
- Shen WC, Ryser HJ. Poly(L-lysine) has different membrane transport and drug carrier properties when complexed with heparin.Proc. Natl Acad. Sci. USA78, 7589–7593 (1981).
- Buschle M, Schmidt W, Zauner W et al. Transloading of tumor antigen-derived peptides into antigen presenting cells. Proc. Natl Acad. Sci. USA94, 3256–3261 (1997).
- Mattner F, Fleitmann JK, Lingnau K et al. Vaccination with poly-L-arginine as immunostimulant for peptide vaccines: induction of potent and long lasting T cell responses against cancer antigens. Cancer Res.62, 1477–1480 (2002).
- Fritz JH, Brunner S, Birnstiel ML et al. The artificial antimicrobial peptide KLKLLLLLKLK induces predominantly a Th2-type immune response to co-injected antigens. Vaccine22, 2374–3284 (2004).
- Uematsu S, Akira S. Toll-like receptors and innate immunity. J. Mol. Med.84, 712–725 (2006).
- Lingnau K, Egyed A, Schellack C, Mattner F, Buschle M, Schmidt W. Poly-L-arginine synergizes with oligodeoxynucleotides containing CpG-motifs (CpG-ODN) for enhanced and prolonged immune responses and prevents the CpG-ODN-induced systemic release of pro-inflammatory cytokines. Vaccine20, 3498–3508 (2002).
- Schijns VEJC. Mechanisms of vaccine adjuvant activity: initiation and regulation of immune response by vaccine adjuvants. Vaccine21, 829–831 (2003).
- Schellack C, Prinz K, Egyed A et al. IC31, a novel adjuvant signaling via TLR9, inducespotent cellular and humoral immune responses. Vaccine24, 5461–5472 (2006).
- Yasuda K, Rutz M, Schlatter B et al. CpG motif-independent activation of TLR9 upon endosomal translocation of ‘natural’ phosphodiester DNA. Eur. J. Imunol.36, 431–436 (2006).
- Agger EM, Rosenkrands I, Olsen AW et al. Protective immunity to tuberculosis with Ag85B–ESAT-6 in a synthetic cationic adjuvant system IC31. Vaccine24, 5452–5460 (2006).
- Graham MB, Braciale TJ. Resistance to and recovery from lethal influenza virus infection in B lymphocyte-deficient mice. J. Exp. Med.186, 2063–2068 (1997).
- Brown DM, Dilzer AM, Meents DL, Swain SL. CD4 T cell-mediated protection from lethal influenza: perforin and antibody-mediated mechanisms give a one–two punch. J. Immunol.177, 2888–2898 (2006).
- Wareing MD, Tannock GA. Route of administration is the prime determinant of IgA and IgG2a responses in the respiratory tract of mice to the cold-adapted live attenuated influenza A donor strain A/Leningrad/134/17/57. Vaccine21, 3097–3100 (2003).
- Gerhard W, Mozdzanowska K, Furchner M, Washko G, Maiese M. Role of the B-cell response in recovery of mice from primary influenza virus infection. Immunol. Rev.159, 95–103 (1997).
- Schlaphoff V, Klade CS, Jilma B et al. Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients. Vaccine25(37–38), 6793–6806 (2007).
- Firbas C, Jilma B, Tauber E et al. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized , placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine24, 4343–4353 (2006).
- Anderson P. Subunit vaccines against tuberculosis. Presented at: Keystone Symposia – Tuberculosis: From Lab Research to Field Trials. Vancouver, Canada, 20–25 March 2007.
- Ottenhoff T. Results from a first clinical safety and immunogenicity Phase 1 trial with a new subunit vaccine against tuberculosis. Presented at: Semmering Conference - Challenges for Vaccine Development: Medical Needs and Social Implications. Baden, Austria, 12–15 April 2007.
Websites
- EMEA www.emea.europa.eu
- US FDA www.fda.gov